



FOR IMMEDIATE RELEASE

Powder Pharmaceuticals Hong Kong Manufacturing Facility is Acceptable by US FDA

Hong Kong, 08 July 2013 - The directors of Lee's Pharmaceutical Holdings Limited ("the Group") are pleased to announce that on 03 July 2013, Powder Pharmaceuticals, Incorporated ("PPI"), an associated company of the Group, received establishment inspection report from the U.S. FDA. The report officially states that "the facility is acceptable". PPI's Hong Kong Manufacturing facility has been inspected and is now registered by the U.S. FDA.

"This is a critical milestone in order to gain approval by the U.S. FDA for the relaunch of Zingo™ in the U.S. This is not only monumental to PPI development but also represents a breakthrough for Hong Kong's effort to become a biotech hub," commented by Dr. Benjamin Li, CEO of PPI.

About Zingo™

Zingo™ is the first needleless, painless powder injection system to be approved for analgesia at an IV/cannula access site. The rapid onset of analgesia in 1-3 minutes provides care givers and patients the opportunity for a pain-free and needle-free access procedure. Zingo™ is approved for use in children over 3 years of age and in adults. Clinical trials have shown a statistical difference in pain scores during needle access procedures when using Zingo™ versus a placebo system.

About PPI

Powder Pharmaceuticals Inc. is a privately held company based in Hong Kong that is developing products that utilize a proprietary needleless, painless, powder delivery technology. Powder Pharmaceuticals intends to supply Zingo™ globally through international business partners. PPI has submitted the amendment with the U.S. FDA for approval of the production of Zingo™ in the new Hong Kong manufacturing facility since 29th October 2012. The submission is being reviewed by the U.S. FDA and the Hong Kong manufacturing facility has been inspected by the U.S. FDA investigators at the end of January 2013.

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.



FOR IMMEDIATE RELEASE

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com